Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Acelrx Pharmaceutica
(NQ:
ACRX
)
1.200
USD
-0.080 (-6.25%)
Official Closing Price
Updated: 7:43 PM EDT, Apr 16, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Acelrx Pharmaceutica
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure
April 08, 2021
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions,...
From
PR Newswire
AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors
March 31, 2021
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...
From
PR Newswire
AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings
March 25, 2021
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...
From
PR Newswire
AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference
March 22, 2021
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions,...
From
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
March 18, 2021
Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at...
From
PR Newswire
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
March 15, 2021
Full year 2020 revenues of $5.4 million compared to $2.3 million in 2019
From
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
March 12, 2021
Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at...
From
PR Newswire
AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021
March 08, 2021
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Monday, March 15, 2021....
From
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
March 03, 2021
Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at...
From
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
February 18, 2021
Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at...
From
PR Newswire
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures
February 17, 2021
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions,...
From
PR Newswire
AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock
January 20, 2021
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions,...
From
PR Newswire
AcelRx Announces Underwritten Public Offering of Common Stock
January 19, 2021
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions,...
From
PR Newswire
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen
January 19, 2021
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions,...
From
PR Newswire
AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements
January 14, 2021
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...
From
PR Newswire
AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA®
December 10, 2020
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...
From
PR Newswire
AcelRx Announces $10 Million Registered Direct Common Stock Offering
December 10, 2020
Investment from existing and new, leading life sciences investors
From
PR Newswire
AcelRx Pharmaceuticals to Present at LD Micro Main Event
December 09, 2020
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings,...
From
PR Newswire
AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association
December 04, 2020
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...
From
PR Newswire
AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA®
November 18, 2020
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...
From
PR Newswire
AcelRx Pharmaceuticals to Present at Credit Suisse 29th Annual Virtual Healthcare Conference
November 06, 2020
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings,...
From
PR Newswire
AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 05, 2020
Third quarter product sales of $1.3M, up significantly compared to $0.3M in the second quarter
From
PR Newswire
AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020
October 29, 2020
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Thursday, November 5, 2020....
From
PR Newswire
Thinking about buying stock in Just Energy, Extreme Networks, Aurora Cannabis, AcelRx Pharmaceuticals, or Rigel Pharmaceuticals?
October 09, 2020
InvestorsObserver issues critical PriceWatch Alerts for JE, EXTR, ACB, ACRX, and RIGL.
From
PR Newswire
AcelRx to Host Virtual KOL Event on Perioperative Use of DSUVIA®
September 29, 2020
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised...
From
PR Newswire
Thinking about buying stock in Athersys, Party City, AcelRx Pharmaceuticals, Southwest Airlines, or Carnival Corp?
September 23, 2020
InvestorsObserver issues critical PriceWatch Alerts for ATHX, PRTY, ACRX, LUV, and CCL.
From
PR Newswire
Thinking about buying stock in Tenax Therapeutics, Boxlight Corp, Blink Charging, Pacific Ethanol, or AcelRx Pharmaceuticals?
September 22, 2020
InvestorsObserver issues critical PriceWatch Alerts for TENX, BOXL, BLNK, PEIX, and ACRX.
From
PR Newswire
AcelRx Awarded U.S. Army Contract for DSUVIA®
September 22, 2020
DSUVIA contract award for up to $3.6 million from the U.S. Army
From
PR Newswire
AcelRx Announces DSUVIA® Added to the U.S. Department of Defense's Joint Deployment Formulary
September 14, 2020
DSUVIA now available to all branches of the military
From
PR Newswire
AcelRx Pharmaceuticals to Present at Two Upcoming Conferences
September 10, 2020
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.